ClinicalTrials.gg
CompletedNCT04387227Updated Nov 20, 2026Results posted

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2 interventional study of Carboplatin and Pembrolizumab in Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma and Recurrent Primary Peritoneal Carcinoma, sponsored by University of Washington. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Washington · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Updated Nov 20, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing pembrolizumab in Fallopian Tube Neoplasms — 1 open to participants now, 5 under way, 1 of them phase 3. pembrolizumab · Fallopian Tube Neoplasms.

Enrollment
13th of 15
22 · median 33
Started
2021
with 3 others
Phase 2
10 of 15
1 open now
Registered
12th of 15
by date
Lead sponsor
2 of 15
University of Washington

Among the 15 studies testing pembrolizumab in Fallopian Tube Neoplasms, this one is the 13th largest by enrollment, is one of 4 that started in 2021, is one of 10 in phase 2, and was the 12th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

1 of the 15 studies testing pembrolizumab in Fallopian Tube Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing pembrolizumab in Fallopian Tube Neoplasms, or all of them as a file.
02

Study summary

This phase II trial investigates how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), when it is detectable by a blood test, CA-125, but not seen on imaging scans. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, but carboplatin has also been shown to stimulate immune responses. Giving pembrolizumab together with carboplatin may work better in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Read the detailed description

OUTLINE:

Patients receive carboplatin intravenously (IV) over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients also undergo blood sample collection on the trial.

After the completion of study treatment, patients are followed up at 30 days, then every 3 months for year 1, and every 6 months for year 2.

03

Conditions studied

  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who have received systemic chemotherapy including platinum-based chemotherapy
  • Have a cancer antigen (CA)-125 that normalized after therapy
  • CA-125 increased to more than twice the or two times the nadir value after most recent second or later line of treatment
  • Have no based on (RECIST) 1.1. Ascites and pleural effusions are not measurable disease, if asymptomatic
  • All patients who are having sex that can lead to pregnancy must agree to for the duration of the study
  • Have estimated of at least 3 months
  • Be willing and able to provide written /assent for the trial
  • Be >= 18 years of age on day of signing informed consent
  • Have a performance status of 0 or 1 on the on the (ECOG) performance scale
  • (ANC) >= 1,500/mcL (performed within 14 days of treatment initiation)
  • >= 100,000/mcL (performed within 14 days of treatment initiation)
  • (Hgb) >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 14 days of treatment initiation)
  • Creatinine =\< 1.5 x upper limit of normal (ULN) OR measured or calculated >= 30 mL/min for subject with creatinine levels > 1.5 x institutional ULN (performed within 14 days of treatment initiation)
  • Total =\< 1.5 X ULN OR direct bilirubin =\< ULN for subjects with total bilirubin levels > 1.5 X ULN (performed within 14 days of treatment initiation)
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 X ULN OR =\< 5 X ULN for subjects with liver (performed within 14 days of treatment initiation)
  • (INR) or prothrombin time (PT) =\< 1.5 X ULN unless patient is receiving anticoagulant therapy (as long as PT or partial thromboplastin time [PTT] is within therapeutic range of intended use of anticoagulants) (performed within 14 days of treatment initiation)
  • Activated partial thromboplastin time (aPTT) or PTT =\< 1.5 X ULN unless patient is receiving anticoagulant therapy (as long as PT or PTT is within therapeutic range of intended use of anticoagulants) (performed within 14 days of treatment initiation)

Exclusion criteria

Exclusion Criteria:

  • Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy within 4 weeks of the first dose of treatment
  • Has a diagnosis of immunodeficiency or is receiving systemic therapy (if dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of trial treatment
  • Short-term administration of systemic steroids (i.e., for allergic reactions or the management of immune-related adverse events [irAEs]) is allowed
  • Has symptomatic ascites or pleural effusions
  • History of borderline or low malignant potential ovarian cancer
  • to pembrolizumab or any of its
  • Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =\< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
  • Has had prior chemotherapy, biologic therapy, targeted small molecule therapy, hormonal therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =\< grade 1 or at baseline) from adverse events due to a previously administered agent

    • Note: Patients with =\< grade 2 neuropathy are an exception to this criterion and may qualify for the study
    • Note: If a patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis. Patients with previously treated may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
  • Has active disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
  • cardiovascular disease
  • Known severe hypersensitivity reactions to monoclonal antibodies or carboplatin >= grade 3, any history of anaphylaxis, or uncontrolled asthma
  • Has received prior therapy with pembrolizumab
  • Has a known history of (HIV) (HIV 1/2 antibodies)
  • Has known active (e.g., hepatitis B surface antigen [HBsAg] reactive) or (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
  • Has received a or live-attenuated vaccine within 30 days of planned start of study therapy. Administration of killed vaccines is allowed

    • Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment (carboplatin, pembrolizumab)

    Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection on the trial.

    Drug: Carboplatin · Biological: Pembrolizumab · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Biospecimen Collection

Interventions

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, JM8

  • BiologicalPembrolizumab

    Given IV

    Also known as: Keytruda, Lambrolizumab, MK-3475, SCH 900475, BCD-201

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT Scan, Computed Axial Tomography, CT SCAN

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: MRI

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection

06

What researchers measure

Primary outcomes

  1. Rate of Radiographic Recurrence

    Time frame: At 6 months

  2. Progression Free Survival

    Time frame: Up to 2 years

Secondary outcomes

  1. Programmed Cell Death Ligand 1 (PD-L1) Expression

    Evaluated by immunohistochemistry staining in combined tumor and inflammatory cells in which positivity will be defined by \> 3% staining. PD-L1 antibody-stained archival tumor was evaluated by a board-certified pathologist and given a Combined Percent Score (CPS), or the overall percentage of positive cells expressing PD-L1, and a CPS ≥ 3% was defined as PD-L1 positive.

    Time frame: Up to 2 years

  2. Changes in T Cell Activation

    Flow cytometry will be performed on peripheral blood mononuclear cells. A 19-parameter flow cytometry panel was performed and summarized with mean range over time, Baseline and Cycle 3.

    Time frame: Baseline and 18 months

  3. Overall Survival

    Analyzed using the Kaplan-Meier method. Kaplan-Meier estimates of the survival function with 95% CIs at specific time points (using Greenwood's formula for the standard error) were computed. Comparisons with the historical control OS will be conducted by examining whether the 95% confidence internal covers the historical control proportions.

    Time frame: Up to 2 years

07

Results

Posted Nov 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Carboplatin, Pembrolizumab)
Started22
Completed22
Not completed0

Outcome measures

PrimaryRate of Radiographic Recurrence
Time frame:
At 6 months
Reported as:
Number · percentage of participants
Rate of Radiographic Recurrence
percentage of participantsTreatment (Carboplatin, Pembrolizumab)
Rate of Radiographic Recurrence36.4
PrimaryProgression Free Survival
Time frame:
Up to 2 years
Reported as:
Median · Months
Progression Free Survival
MonthsTreatment (Carboplatin, Pembrolizumab)
Progression Free Survival5.28 (2.53 to 8.73)
SecondaryProgrammed Cell Death Ligand 1 (PD-L1) Expression

Evaluated by immunohistochemistry staining in combined tumor and inflammatory cells in which positivity will be defined by \> 3% staining. PD-L1 antibody-stained archival tumor was evaluated by a board-certified pathologist and given a Combined Percent Score (CPS), or the overall percentage of positive cells expressing PD-L1, and a CPS ≥ 3% was defined as PD-L1 positive.

Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryChanges in T Cell Activation

Flow cytometry will be performed on peripheral blood mononuclear cells. A 19-parameter flow cytometry panel was performed and summarized with mean range over time, Baseline and Cycle 3.

Time frame:
Baseline and 18 months

Results for this outcome have not been posted.

SecondaryOverall Survival

Analyzed using the Kaplan-Meier method. Kaplan-Meier estimates of the survival function with 95% CIs at specific time points (using Greenwood's formula for the standard error) were computed. Comparisons with the historical control OS will be conducted by examining whether the 95% confidence internal covers the historical control proportions.

Time frame:
Up to 2 years

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events will be recorded from the time of consent through the Safety Follow Up Visit (each patient will be followed for 30 days or prior to initiation of new treatment. This could be up to 2 years of evaluation. If there is an ongoing serious adverse event the patient will be followed for a total of 90 days after the end of their treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Carboplatin, Pembrolizumab)10/22 (45.5%)0/22 (0%)20/22 (90.9%)
Most frequent other events
Showing 10 of 96
Most frequent other events
EventTreatment (Carboplatin, Pembrolizumab)
FatigueGastrointestinal disorders12/22
NauseaGastrointestinal disorders10/22
DiarrheaGastrointestinal disorders7/22
Abdominal PainGastrointestinal disorders5/22
PainGeneral disorders5/22
DyspneaRespiratory, thoracic and mediastinal disorders4/22
Upper Respiratory InfectionInfections and infestations4/22
HeadacheNervous system disorders4/22
HoarsenessRespiratory, thoracic and mediastinal disorders3/22
MyalgiaMusculoskeletal and connective tissue disorders3/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Carboplatin, Pembrolizumab)
<=18 years0
Between 18 and 65 years11
>=65 years11
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Carboplatin, Pembrolizumab)
Female22
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Carboplatin, Pembrolizumab)
Hispanic or Latino1
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Carboplatin, Pembrolizumab)
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Carboplatin, Pembrolizumab)
United States22
08

Study locations

1 site
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Liao JB, Gwin WR, Urban RR, Hitchcock-Bernhardt KM, Coveler AL, Higgins DM, Childs JS, Shakalia HN, Swensen RE, Stanton SE, Tinker AV, Wahl TA, Ancheta RG, McGonigle KF, Dai JY, Disis ML, Goff BA. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. J Immunother Cancer. 2021 Sep;9(9):e003122. doi: 10.1136/jitc-2021-003122. PubMed 34531249 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Sep 2025, 53 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Of 98 non-industry phase 2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 53 months is below that.

Counting every sponsor, half of 125 studies reached it within 56 months; a quarter within 42 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 13, 2020
StartActual
Mar 18, 2021
Primary completionActual
Sep 12, 2025
CompletionActual
Jun 1, 2026
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedProgression-free survival Free SurvivalTime frame: At 6 months → Up to 2 years
  • EditedRate of radiographic recurrenceRadiographic RecurrenceTime frame: At 6 months
Nov 20, 2026
Documents
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedProgrammed cell death ligandCell Death Ligand 1 (PD-L1) expressionExpressionTime frame: Up to 2 years
  • EditedChanges in T cell activationCell ActivationTime frame: Baseline and 2 years → Baseline and 18 months
  • EditedOverall survivalSurvivalTime frame: Up to 2 years
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedProgression-free survival Free SurvivalTime frame: At 6 months → Up to 2 years
    • EditedRate of radiographic recurrenceRadiographic RecurrenceTime frame: At 6 months
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedProgrammed cell death ligandCell Death Ligand 1 (PD-L1) expressionExpressionTime frame: Up to 2 years
    • EditedChanges in T cell activationCell ActivationTime frame: Baseline and 2 years → Baseline and 18 months
    • EditedOverall survivalSurvivalTime frame: Up to 2 years
    + 5 other changes: responsible party, description, contact details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04387227
Collaborators
National Cancer Institute (NCI), United States Department of Defense
Responsible party
John Liao (Associate Professor, University of Washington) — Principal investigator
First posted
May 13, 2020
Start date
Mar 18, 2021
Primary completion
Sep 12, 2025
Completion
Jun 1, 2026
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

John B. Liao, MD, PhD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion